Skip to main content

Pharma Mar

PharmaMar SA is a Spanish biopharmaceutical enterprise focused on discovering, developing, and commercializing marine-derived oncology drugs. The company develops antitumor therapies including Yondelis (trabectedin) for soft tissue sarcoma and Zepzelca (lurbinectedin) for small cell lung cancer, alongside marine biotechnology applications. Principal revenues derive from commercial prescription drug sales, international licensing royalty fees, upfront partnership payments, and active pharmaceutical ingredient supply. Core end markets encompass medical oncology clinics, hospital networks, specialty prescription patients, and global pharmaceutical distribution partners across Europe, the US, and Asia-Pacific. PharmaMar holds a market-leading global position in marine-derived biopharmaceutical drug discovery and targeted oncology therapeutics. The corporation is headquartered in Colmenar Viejo, Spain, and its shares trade on the Mercado Continuo of the Spanish stock exchanges.

3 of the funds FundTelligence covers report a position in Pharma Mar.

Legal name
PHARMA MAR SA
Sector
Health Care
Country
Spain
Funds holding it
3

Funds holding Pharma Mar

Loading...